PDGFB and myocardial infarction: We used the Pdgfb–iCreERT2 driver line, a widely used tamoxifen-inducible EC-specific Cre, which displays strong activity in coronary ECs during heart development and after MI (Claxton et al., 2008; Dube et al., 2017; Li et al., 2019; Luo et al., 2021; Travisano et al., 2019).